Subcutaneous ICD reduces lead-related complications without compromising effectiveness of ICD shocks

Published On 2022-11-10 14:00 GMT   |   Update On 2022-11-10 14:00 GMT

Implantable cardioverter defibrillators (ICDs) improve survival in patients at risk for cardiac arrest, but are associated with intravascular lead-related complications.

Researchers have found in a randomized multicenter ATLAS trial that Subcutaneous implantable cardioverter defibrillators are associated with 92 percent reduction in lead-related complications typical in patients with ICDs.

The trial conducted on more than 500 persons revealed that subcutaneous implantable cardioverter defibrillators (S-ICDs) reduce perioperative, lead-related complications without significantly compromising the effectiveness of ICD shocks. However they were associated  with more early postoperative pain and a trend for more inappropriate shocks.

Advertisement

The study is published in Annals of Internal Medicine.

ICDs improve survival in patients at risk for cardiac arrest but are associated with intravascular lead-related complications. The S-ICD, with no intravascular components, was developed to minimize lead-related complications.

Researchers from McMaster University conducted a randomized multicenter trial of 544 persons with a primary or secondary prevention indication for an ICD. The authors found that S-ICD usage demonstrated a 92 percent reduction of lead-related complications and prevented most lead-related perioperative complications, including myocardial perforation, which can lead to death. They also reported a modest reduction in system reliability with the S-ICD, specifically a trend toward more inappropriate shocks. After a mean follow-up of 2.5 years, there was a nonsignificant 22 percent reduction in the need for surgical ICD revision with the S-ICD and ongoing, longer-term follow-up of ATLAS participants will evaluate the effect that the S-ICD will have on chronic ICD performance and the need for ICD reoperation.

Reference:

Jeff S. Healey, Andrew D. Krahn, Jamil Bashir,  Guy Amit, François Philippon, William F. McIntyre, Bernice Tsang, Jacqueline Joza, Derek V. Exner, David H. Birnie, Mouhannad Sadek, Darryl P. Leong, Markus Sikkel, Victoria Korley, John L. Sapp, Jean-Francois Roux,  Shun Fu Lee, Gloria Wong, Angie Djuric, Danna Spears, Sandra Carroll, Eugene Crystal, Tom Hruczkowski, Stuart J. Connolly, and Blandine Mondesert, https://doi.org/10.7326/M22-1566

Tags:    
Article Source : Annals of Internal Medicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News